Evidence map›Paper›PMID 40748358›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2025

Update on sleep disorders in advanced Parkinson's disease: a narrative review.

Emmanuel Roze, Monika Rudzinska, Tove Henriksen, Eero Pekkonen, Michal Minar, Artur Druzdz, Bo Biering-Sørensen, Anders Johansson, Smaranda Leu-Semenescu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emmanuel RozeParis Brain Institute, Inserm, CNRS, and AP-HP, Salpêtrière Hospital, Sorbonne University, 47-83 Bd de l'Hôpital, Paris, 75013, France. flamand.roze.75012@gmail.com.ORCID 0000-0001-9727-3459
Monika RudzinskaDepartment of Neurology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.
Tove HenriksenMovement Disorder Clinic, University Hospital of Bispebjerg, Copenhagen, Denmark.
Eero PekkonenDepartment of Neurology, Helsinki University Hospital, Helsinki, Finland.
Michal MinarSecond Department of Neurology, Faculty of Medicine, Comenius University Bratislava, Bratislava, Slovakia.
Artur DruzdzDepartment of Neurology, Municipal Hospital, Poznań, Poland.
Bo Biering-SørensenNeurological Department, Movement Disorder and Pain Research Center, Rigshospitalet, Copenhagen, Denmark.
Anders JohanssonMedical Unit Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Smaranda Leu-SemenescuParis Brain Institute, Inserm, CNRS, and AP-HP, Salpêtrière Hospital, Sorbonne University, 47-83 Bd de l'Hôpital, Paris, 75013, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple types of sleep disorders are encountered in patients with Parkinson's disease (PD) and are often underreported and underdiagnosed. They include circadian disorders, insomnia, excessive daytime sleepiness, rapid-eye-movement-sleep behavioral disorder, restless legs syndrome, and obstructive sleep apnea. The prevalence of sleep problems increases early in the disease course, and sleep quality deteriorates overall as patients age and the disease progresses. At advanced stages of PD, there is a reciprocal link between sleep problems and PD manifestations: sleep problems tend to exacerbate motor and non-motor symptoms, while worsening of motor and non-motor conditions have a detrimental effect on sleep quality. As the disease advances, sleep disorders have a growing negative influence on the quality of life of both patients and family caregivers. The causes of sleep disorders in this setting are neurodegeneration of key brain structures involved in sleep, motor and non-motor manifestations interfering with sleep, and drugs interfering with sleep. Treatment can include optimisation of antiparkinsonian treatment, reduction or removal of drugs interfering with sleep, treatment of non-motor manifestations interfering with sleep, pharmacological treatment of specific sleep disorders, and non-pharmacological approaches. Efforts should be made to raise awareness among patients, families, students, physicians, charities, funders, and policy makers regarding the prevalence and consequences of sleep disorders in advanced PD.

Indexed as

Parkinson DiseaseSleep Wake DisordersHumansCircadian disordersExcessive daytime sleepinessInsomniaObstructive sleep apneaREM sleep behavior disorderRestless legs syndrome

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.